Skip to Main Content
Portland Press Logo
header search
Search
Advanced Search
Skip Nav Destination

Non-HDL cholesterol and apoB in dyslipidaemia

Clin Sci (Lond) (2008) 114 (2): 149–155.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
Association of non-HDL cholesterol with plaque burden and composition of culprit lesion in acute coronary syndrome. An intravascular ultrasound-virtual histology study
  • Sreenivas Reddy
  • Raghavendra Rao K
  • Jeet Ram Kashyap
  • Vikas Kadiyala
  • Suraj Kumar
  • Debabrata Dash
  • Lipi Uppal
  • Jaspreet Kaur
  • Manpreet Kaur
  • Hithesh Reddy
  • Imran Ibni Gani Rather
  • Samir Malhotra
Indian Heart Journal (2024) 76 (5): 342.
A More Atherogenic Lipoprotein Status Is Present in Adults With Type 2 Diabetes Mellitus Than in Those Without With Equivalent Degrees of Hypertriglyceridemia
  • Cathy J. Sun
  • Diane Brisson
  • Rahul Sharma
  • Nicholas Birkett
  • Daniel Gaudet
  • Teik C. Ooi
Canadian Journal of Diabetes (2022) 46 (5): 480.
Lipoprotein Particle Predictors of Arterial Stiffness after 17 Years of Follow Up: The Malmö Diet and Cancer Study
  • Jacob Hartz
  • Ronald M. Krauss
  • Mikael Göttsater
  • Olle Melander
  • Peter Nilsson
  • Michele Mietus-Snyder
International Journal of Vascular Medicine (2020) 2020: 1.
Nonfasting versus fasting lipid profile for cardiovascular risk prediction
  • Anne Langsted
  • Børge G. Nordestgaard
Pathology (2019) 51 (2): 131.
Did the ACC/AHA/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA cholesterol guidelines get apoB right?
  • Allan D. Sniderman
Journal of Clinical Lipidology (2019) 13 (3): 360.
High triglyceride levels alter the correlation of apolipoprotein B with low- and non-high-density lipoprotein cholesterol mostly in individuals with diabetes or metabolic syndrome
  • Fotios Barkas
  • Moses Elisaf
  • Evangelos Liberopoulos
  • Angelos Liontos
  • Evangelos C. Rizos
Atherosclerosis (2016) 247: 58.
Guías 2013 ACC/AHA riesgo cardiovascular. De evidencias incompletas y fallido intento de simplificación
  • Pablo Corral
Clínica e Investigación en Arteriosclerosis (2015) 27 (2): 74.
Calculation of LDL apoB
  • Allan D. Sniderman
  • André J. Tremblay
  • Jacqueline De Graaf
  • Patrick Couture
Atherosclerosis (2014) 234 (2): 373.
Strategies for vascular disease prevention: The role of lipids and related markers including apolipoproteins, low-density lipoproteins (LDL)-particle size, high sensitivity C-reactive protein (hs-CRP), lipoprotein-associated phospholipase A2 (Lp-PLA2) and lipoprotein(a) (Lp(a))
  • Dhayana Dallmeier
  • Wolfgang Koenig
Best Practice & Research Clinical Endocrinology & Metabolism (2014) 28 (3): 281.
Discordance between non-HDL-cholesterol and LDL-particle measurements: Results from the Multi-Ethnic Study of Atherosclerosis
  • Emil M. deGoma
  • Mat D. Davis
  • Richard L. Dunbar
  • Emile R. Mohler
  • Philip Greenland
  • Benjamin French
Atherosclerosis (2013) 229 (2): 517.
Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia
  • Michel Farnier
  • John R. Guyton
  • Erin Jensen
  • Adam B. Polis
  • Amy O. Johnson-Levonas
  • Philippe Brudi
Atherosclerosis (2013) 229 (2): 415.
Phenotypes of hypertriglyceridemia caused by excess very-low-density lipoprotein
  • Allan D. Sniderman
  • Andre Tremblay
  • Jacqueline De Graaf
  • Patrick Couture
Journal of Clinical Lipidology (2012) 6 (5): 427.
A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk
  • Allan D. Sniderman
  • Ken Williams
  • John H. Contois
  • Howard M. Monroe
  • Matthew J. McQueen
  • Jacqueline de Graaf
  • Curt D. Furberg
Circulation: Cardiovascular Quality and Outcomes (2011) 4 (3): 337.
Influence of simvastatin, fenofibrate and/or ezetimibe on correlation of low-density lipoprotein and nonhigh-density lipoprotein cholesterol with apolipoprotein B in mixed dyslipidemic patients
  • Michel Farnier
  • William Taggart
  • Qian Dong
  • Jianxin Lin
  • Arvind Shah
  • Philippe Brudi
Journal of Clinical Lipidology (2011) 5 (3): 179.
Comparisons of Apolipoprotein B Levels Estimated by Immunoassay, Nuclear Magnetic Resonance, Vertical Auto Profile, and Non-High-Density Lipoprotein Cholesterol in Subjects With Hypertriglyceridemia (SAFARI Trial)
  • Scott M. Grundy
  • Gloria Lena Vega
  • Joanne E. Tomassini
  • Andrew M. Tershakovec
The American Journal of Cardiology (2011) 108 (1): 40.
Cardiovascular screening: which populations, what measures of risk?
  • A. S. Wierzbicki
International Journal of Clinical Practice (2011) 65 (1): 3.
Triglycerides and Cardiovascular Disease
  • Michael Miller
  • Neil J. Stone
  • Christie Ballantyne
  • Vera Bittner
  • Michael H. Criqui
  • Henry N. Ginsberg
  • Anne Carol Goldberg
  • William James Howard
  • Marc S. Jacobson
  • Penny M. Kris-Etherton
  • Terry A. Lennie
  • Moshe Levi
  • Theodore Mazzone
  • Subramanian Pennathur
Circulation (2011) 123 (20): 2292.
LDL-C or apoB as the best target for reducingcoronary heart disease: should apoB be implemented into clinical practice?
  • Helena Vaverkova
Clinical Lipidology (2011) 6 (1): 35.
Comparison of the efficacy of fibrates on hypertriglyceridemic phenotypes with different genetic and clinical characteristics
  • Diane Brisson
  • Julie Méthot
  • Karine Tremblay
  • Monique Tremblay
  • Patrice Perron
  • Daniel Gaudet
Pharmacogenetics and Genomics (2010) 20 (12): 742.
Correlation of Non–High-Density Lipoprotein Cholesterol and Low-Density Lipoprotein Cholesterol With Apolipoprotein B During Simvastatin + Fenofibrate Therapy in Patients With Combined Hyperlipidemia (A Subanalysis of the SAFARI Trial)
  • Scott M. Grundy
  • Gloria Lena Vega
  • Joanne E. Tomassini
  • Andrew M. Tershakovec
The American Journal of Cardiology (2009) 104 (4): 548.
ApoB versus non-HDL-C: What to do when they disagree
  • Allan Sniderman
  • Ken Williams
  • Christa Cobbaert
Current Atherosclerosis Reports (2009) 11 (5): 358.
Targets for LDL-lowering therapy
  • Allan Sniderman
Current Opinion in Lipidology (2009) 20 (4): 282.
Effects of Aerobic Exercise on Non–High-Density Lipoprotein Cholesterol in Children and Adolescents
  • Keith Tolfrey
The Physician and Sportsmedicine (2009) 37 (2): 162.
Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice
  • Allan D. Sniderman
Journal of Clinical Lipidology (2008) 2 (1): 36.
  • Online ISSN 1470-8736
  • Print ISSN 0143-5221

CONNECT

EXPLORE

Portland Press

Registered address – First Floor, 10 Queen Street Place, London EC4R 1BE

  • Portland Press Tel
  • +44 (0)20 3880 2795
  • Portland Press Company no. 02453983

  • Biochemical Society Tel
  • +44 (0)20 3880 2793
  • Email: [email protected]

  • Biochemical Society Company no. 00892796
  • Registered Charity no. 253894
  • VAT no. GB 523 2392 69
.
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept